3 news items
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
BHVN
29 May 24
and multiple ascending dose study with BHV-8000 in healthy subjects, including evidence of target engagement (i.e., biomarker reductions in high
Reported Saturday, Biohaven Showcased Innovative Neuroscience Portfolio With 20 Presentations At The 2024 AAN Annual Meeting
BHVN
15 Apr 24
Safety, tolerability, and target engagement data showing the differentiated profile of BHV-7000 as a potential best-in-class Kv7 activator
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
BHVN
13 Apr 24
Safety, tolerability, and target engagement data showing the differentiated profile of BHV-7000 as a potential best
- Prev
- 1
- Next